Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2000
05/17/2000EP1000056A1 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
05/17/2000EP1000055A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
05/17/2000EP1000054A1 Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them
05/17/2000EP1000053A1 Macrocyclic lactones, compositions, and methods of use
05/17/2000EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4
05/17/2000EP1000048A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
05/17/2000EP1000047A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
05/17/2000EP1000046A1 Piperazine derivatives active on the lower urinary tract
05/17/2000EP1000045A1 1,4-disubstituted piperazines
05/17/2000EP1000044A1 Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists
05/17/2000EP1000043A1 A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
05/17/2000EP1000041A1 1,3-diaza- heterocycles and their use as nitric oxide synthase inhibitors
05/17/2000EP1000040A1 Il-5 inhibiting 6-azauracil derivatives
05/17/2000EP1000039A1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
05/17/2000EP1000038A1 Novel pyrimidin derivatives
05/17/2000EP1000036A1 Hydantoin derivatives having an inhibitory activity for farnesyl transferase
05/17/2000EP1000035A1 Substituted 6-phenylphenanthridines
05/17/2000EP1000034A1 Substituted 6-alkylphenanthridines
05/17/2000EP1000033A1 Heterocyclic derivatives which inhibit factor xa
05/17/2000EP1000031A1 Vitronectin receptor antagonist
05/17/2000EP1000029A1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
05/17/2000EP1000028A1 Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
05/17/2000EP1000027A1 Thermodynamically stable modification of 1-(4-carbazolyloxy)-3- 2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
05/17/2000EP1000026A1 Special 3-azabicyclo 3.1.0]hexanes, method for producing and modifying the same, and their use
05/17/2000EP1000024A1 Mercaptoacylamino acids as metallo-beta-lactamase inhibitors
05/17/2000EP1000023A2 Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
05/17/2000EP1000018A2 Urokinase inhibitors
05/17/2000EP1000017A1 Il-8 receptor antagonists
05/17/2000EP1000015A1 Bicyclic metabotropic glutamate receptor ligands
05/17/2000EP1000012A1 Process for converting propargylic amine-n-oxides to enaminones
05/17/2000EP1000008A1 Novel thyroid receptor ligands and method
05/17/2000EP0999856A2 Radiopharmaceuticals for imaging infection and inflammation
05/17/2000EP0999855A1 Polymer based pharmaceutical compositions for targeted delivery of biologically active agents
05/17/2000EP0999849A1 Therapeutic agent for the treatment of septicaemia, its preparation and use
05/17/2000EP0999847A1 Health supplement
05/17/2000EP0999846A1 Phosphatidic acid-based immune modulator composition
05/17/2000EP0999845A1 Treatment of diabetes with thiazolidinedione and sulphonylurea
05/17/2000EP0999844A1 Pretreating hyperlipidemic individuals with a flush inhibiting agent prior to nicotinic acid therapy
05/17/2000EP0999843A1 Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
05/17/2000EP0999842A1 Novel substituted imidazole compounds
05/17/2000EP0999841A1 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
05/17/2000EP0999840A1 Use of draflazine-analogues for treating pain
05/17/2000EP0999839A1 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
05/17/2000EP0999838A1 Self-emulsifying formulation for lipophilic compounds
05/17/2000EP0999837A1 Treatment of diabetes with rosiglitazone and insulin
05/17/2000EP0999836A1 A pharmaceutical composition active in reducing production of mcp-1 protein
05/17/2000EP0999835A1 Imidazole derivatives as mdr modulators
05/17/2000EP0999834A1 Antithrombotic agents
05/17/2000EP0999833A1 Taxol emulsion
05/17/2000EP0999832A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols
05/17/2000EP0999831A1 Use of petroselinum acid for treating inflammations
05/17/2000EP0999830A1 Sertraline salts and sustained-release dosage forms of sertraline
05/17/2000EP0999829A1 Solubilized sertraline compositions
05/17/2000EP0999828A2 Method for producing active agent preparations with controlled release from a matrix
05/17/2000EP0999826A1 Self-emulsifying formulation for lipophilic compounds
05/17/2000EP0999825A1 Ophthalmic compositions containing galactomannan polymers and borate
05/17/2000EP0999819A2 Physiological combination of active substances to enhance the skin's defenses against noxious agents
05/17/2000EP0999757A1 Nutritional composition for subjects under stress
05/17/2000EP0871437B1 Use of boswellic acid for treating brain tumours
05/17/2000EP0841917A4 Method of treatment for exercise-induced pulmonary hemorrhage in racing stock
05/17/2000EP0831767A4 Alpha hydroxyacid esters for skin aging
05/17/2000EP0804413B1 Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production
05/17/2000EP0804191B1 Use of inhibitors of platelet derived growth receptor for the manufacture of a medicament for the treatment of cancers
05/17/2000EP0796238B1 Method of stabilizing polyunsaturated fatty acids and their application in therapy and cosmetics
05/17/2000EP0791072B1 Process for determining the activity of specific phosphotyrosine phosphatases and specific effectors thereof in intact cells
05/17/2000EP0776202B1 Liposome-encapsulated taxol, its preparation and its use
05/17/2000EP0773950A4 Linked peptide nucleic acids
05/17/2000EP0770066B1 Serotonin 5-ht 1a and dopamin d2 receptor ligands
05/17/2000EP0731706B1 Use of dimeticone for the manufacture of a medicament for treating aphthae and stomatitis
05/17/2000EP0726768B1 Use of nitric oxide releasing compounds for the manufacture of a medicament for protection in ischemia reperfusion injury
05/17/2000EP0707483A4 Methods for inhibiting skin ulceration by use of cyanoacrylate adhesives
05/17/2000EP0702699B1 Sulfated hyaluronic acid wherein the number of sulfate groups per repetitive unit is from 0.5 to less than 2
05/17/2000EP0689426B1 Therapeutic agent for the treatment of melanomas
05/17/2000EP0653911B1 Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
05/17/2000EP0644764B1 Lipids for epidermal moisturization and repair of barrier function
05/17/2000EP0605700B1 Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
05/17/2000EP0553272B1 Synthetic lung surfactant
05/17/2000CN1253590A Bacterial plasmids
05/17/2000CN1253588A Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
05/17/2000CN1253587A Methods and compositions for synthesis of long chain polyunsaturated fatty acids
05/17/2000CN1253565A Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines
05/17/2000CN1253563A Nitrate esters of corticoid compounds and pharmaceutical applications thereof
05/17/2000CN1253561A Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5) for treatment of sexual dysfunction
05/17/2000CN1253560A Sulfonamides for treatment of endothelin-mediated disorders
05/17/2000CN1253559A Sulfonyl divalent aryl alpha-hydroxamic acid compounds
05/17/2000CN1253558A Substituted imidazoles useful in treatment of inflammatory diseases
05/17/2000CN1253557A Vitamin D3 analogs with bis C-20 side chains
05/17/2000CN1253555A Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
05/17/2000CN1253554A Heterocyclic compounds and their use for inhibiting 'beta'-amyloid peptide
05/17/2000CN1253553A Substituted phenyl derivatives, their preparation and use
05/17/2000CN1253551A Pyrazine compounds
05/17/2000CN1253549A Benzimidazole derivative
05/17/2000CN1253548A HIV protease inhibitors
05/17/2000CN1253547A 1,4-substituted cyclic amine derivatives
05/17/2000CN1253545A Aryl sulfonamides and analogues thereof and their use in treatment of neurodegenerative diseases
05/17/2000CN1253544A Solid compositions suitable for oral administration comprising L-carnitine or alkanoyl-L-carnitine magnesium fumarate
05/17/2000CN1253508A Topical nasal antiinflammatory compositions
05/17/2000CN1253505A Pourable alginate compositions
05/17/2000CN1253504A Cytokine related treatments of disease
05/17/2000CN1253503A Stabilized tibolone compositions
1 ... 6317 6318 6319 6320 6321 6322 6323 6324 6325 6326 6327 6328 6329 6330 6331 6332 6333 6334 6335 6336 6337 ... 7860